This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Pivotal Trial Results
Post-Hoc Analysis Results
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
+TCS
Without TCS
JADE COMPARE evaluated efficacy and safety endpoints up to 16 weeks in a randomized, double-blind, double-dummy, placebo-controlled, parallel-group clinical trial in which 837 patients aged 18 years and older with moderate-to-severe AD received CIBINQO 100 mg, CIBINQO 200 mg, dupilumab 300 mg, or placebo, with background TCS in all arms. Dupilumab was an active control except for the one head-to-head endpoint of PP-NRS4 at week 2. Patients had a history of inadequate response to topical therapies or required systemic therapy.1-3
See full study design >
RECOMMENDED DOSE: CIBINQO 100 mg
If response to 100 mg is inadequate, consider increasing to 200 mg. Discontinue if inadequate response is seen after dose increase.
JADE TEEN evaluated efficacy and safety endpoints up to 12 weeks in a phase 3, randomized, double-blind, placebo-controlled clinical trial in which 284 pediatric patients aged 12 to <18 years with a body weight of ≥25 kg and moderate-to-severe AD received CIBINQO 100 mg, CIBINQO 200 mg, or placebo with background TCS in all arms.1,2
See full study design >
PP-NRS4 in pediatric patients 12 to <18 from JADE TEEN (key secondary endpoint)1,2
The proportion of pediatric patients who achieved PP-NRS4 at week 2 was higher with CIBINQO 100 mg (13%) and 200 mg (25%) compared to placebo (8%).†
See data showing absolute change from baseline itch
JADE MONO-1 and MONO-2 evaluated efficacy and safety endpoints up to 12 weeks in two identically designed double-blind, placebo-controlled clinical trials in which 778 patients aged 12 and older with moderate-to-severe AD received CIBINQO 100 mg, CIBINQO 200 mg, or placebo.1,2
See full study design >
RECOMMENDED DOSE: CIBINQO 100 mg
If response to 100 mg is inadequate, consider increasing to 200 mg. Discontinue if inadequate response is seen after dose increase.
A higher proportion of patients treated with CIBINQO 100 mg or 200 mg achieved improvement in itching at week 12 vs placebo.1,2
Similar results were observed in MONO-1.1,2
Consider CIBINQO for patients 12+ with refractory, moderate-to-severe AD when other systemics are inadequate or inadvisable.
See data showing absolute change from baseline itch
Resources such as the discussion guide and patient brochure can help
A product representative is available to help you learn more about CIBINQO
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.